McBarron Paul 4
4 · Cyclacel Pharmaceuticals, Inc. · Filed Jan 7, 2019
Insider Transaction Report
Form 4
McBarron Paul
DirectorEVP, Finance, CFO, COO
Transactions
- Award
Option
2019-01-04+270,079→ 270,079 totalExercise: $0.71Exp: 2029-01-04→ Common Stock (270,079 underlying) - Award
Option
2019-01-03+13,021→ 13,021 totalExercise: $1.74Exp: 2027-12-29→ Common Stock (13,021 underlying) - Award
Option
2019-01-03+11,980→ 11,980 totalExercise: $1.56Exp: 2028-02-22→ Common Stock (11,980 underlying)
Footnotes (4)
- [F1]These securities are exercisable over a three-year period, with 1/36 of the options granted vesting on a monthly basis.
- [F2]These securities were granted as part of the Issuer's annual compensation review to executive officers.
- [F3]On December 29, 2017, Paul McBarron was granted an option to purchase certain shares of common stock, which option shall vest according to the satisfaction of performance criteria. Certain performance criteria were confirmed to have been met on January 3, 2019, resulting in the vesting of the option as to 13,021 shares.
- [F4]On February 22, 2018, Paul McBarron was granted an option to purchase certain shares of common stock, which option shall vest according to the satisfaction of performance criteria. Certain performance criteria were confirmed to have been met on January 3, 2019, resulting in the vesting of the option as to 11,980 shares.